Phio Pharmaceuticals Corp. filings document material events for a clinical-stage siRNA biopharmaceutical company developing INTASYL® gene-silencing therapeutics in immuno-oncology. Recent 8-K disclosures report quarterly and year-end financial results, PH-762 clinical and safety updates, tumor-response data, and development activities for skin cancer indications including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
The company's regulatory record also covers material agreements and capital-structure matters, including a cGMP drug-product manufacturing services agreement for PH-762 clinical supply and an at-the-market common-stock offering under a shelf registration statement. Governance disclosures include executive employment-agreement amendments and related compensatory arrangements.
Phio Pharmaceuticals Corp. announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance, the active pharmaceutical ingredient for its lead clinical program. The company described the completed batch as an operational milestone supporting supply-chain readiness and advancing PH-762 to the next stage of clinical development.
The validated drug substance will proceed through final drug-product completion for Phio’s planned Phase 2b clinical study, which is expected to be initiated in the first quarter of 2027. Phio said the milestone also supports its clinical development and potential commercialization strategy for PH-762.
Phio Pharmaceuticals Corp. (PHIO) director Ronald Todd Plott reported direct purchases of 5,000 common shares on September 28, 2026, at $1.03 per share and 5,000 shares on September 29, 2026, at $1.04 per share. The Rule 10b5-1 plan checkbox was unchecked.
Phio Pharmaceuticals Corp. Chief Financial Officer Lisa Cabott Carson received an award covering 108,000 shares on September 28, 2026. Her reported holdings after the award were 189,112 shares, including shares of common stock underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. reported that Chairman, Pres. & CEO Robert J. Bitterman received a grant covering 400,000 common shares underlying restricted stock units on September 28, 2026. The underlying shares will vest on the first annual anniversary of the grant. His reported post-transaction holdings were 764,871 shares, including shares underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. director Ronald Todd Plott received a grant covering 17,000 shares underlying restricted stock units on September 28, 2026. The transaction was reported as a direct grant/award acquisition. His reported direct holdings following the transaction were 32,000 shares, including common stock underlying unvested restricted stock units.
Phio Pharmaceuticals Corp. stockholders approved an amendment to the 2020 Long Term Incentive Plan at the September 28, 2026 annual meeting. Effective upon stockholder approval, the amendment increased shares available for issuance by 1,500,000, bringing the plan total to 2,452,017 shares.
Stockholders also ratified Grant Thornton, LLP as the independent registered public accounting firm for the year ending December 31, 2026. The plan amendment received 1,155,945 votes for, 194,070 against and 34,468 abstentions; 3,823,097 broker non-votes were reported. At the August 4, 2026 record date, Phio had 11,617,250 common shares issued and outstanding, and 5,207,580 shares were present virtually or represented by valid proxy at the meeting.
Phio Pharmaceuticals Corp. director Patricia A. Bradford purchased 6,500 shares of common stock on September 24, 2026, at $1.0127 per share. Her reported direct holdings after the purchase were 64,151 shares, including shares of common stock underlying unvested restricted stock units. No Rule 10b5-1 plan is reported for the purchase.
Phio Pharmaceuticals Corp. reported that Chairman, President and CEO Robert J. Bitterman purchased 2,000 common shares on September 22, 2026, at $1.0289 per share. His reported direct holdings after the purchase were 364,871 shares, including common stock underlying unvested restricted stock units. No Rule 10b5-1 plan is reported.
Phio Pharmaceuticals Corp. (PHIO) director Patricia A. Bradford purchased common stock on September 15, 2026. She bought 12,000 shares of common stock at $1.03 per share in an open-market or private transaction, increasing her direct holdings to 57,651 shares, which includes shares underlying unvested restricted stock units.
No Rule 10b5-1 trading plan is reported for this transaction.
Phio Pharmaceuticals Corp. (PHIO) reported a Form 4 for Chief Financial Officer Lisa Cabott Carson showing a disposition related to tax withholding. On September 11, 2026, the issuer withheld 12,888 shares of common stock at $1.03 per share to satisfy her tax withholding obligations upon vesting of restricted stock units; no shares were sold in the market. After this transaction, she held 81,112 shares directly, including shares underlying unvested restricted stock units.